% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Mohaupt:274026,
      author       = {Mohaupt, Pablo and Kindermans, Jana and Vialaret, Jérôme
                      and Anderl-Straub, Sarah and Werner, Leonie and Lehmann,
                      Sylvain and Hirtz, Christophe and Otto, Markus and Oeckl,
                      Patrick},
      title        = {{B}lood-based biomarkers and plasma {A}β assays in the
                      differential diagnosis of {A}lzheimer's disease and
                      behavioral-variant frontotemporal dementia.},
      journal      = {Alzheimer's research $\&$ therapy},
      volume       = {16},
      number       = {1},
      issn         = {1758-9193},
      address      = {London},
      publisher    = {BioMed Central},
      reportid     = {DZNE-2025-00007},
      pages        = {279},
      year         = {2024},
      abstract     = {The differentiation between Alzheimer's disease (AD) and
                      behavioral-variant frontotemporal dementia (bvFTD) can be
                      complicated in the initial phase by shared symptoms and
                      pathophysiological traits. Nevertheless, advancements in
                      understanding AD's diverse pathobiology suggest the
                      potential for establishing blood-based methods for
                      differential diagnosis.We devised a novel assay combining
                      immunoprecipitation and mass spectrometry (IP-MS) to
                      quantify Amyloid-beta (Aβ) peptides in plasma. We then
                      assessed its performance against existing assays (Shimadzu
                      and Simoa) and evaluated a range of other blood-based
                      biomarkers, including GFAP, NfL, and pTau-181, for
                      differentiating between AD and bvFTD.The novel IP-MS assay
                      measuring the Aβ42/40 ratio demonstrated an AUC of 0.82 for
                      differentiating AD from control subjects. While it did not
                      significantly outperform the composite biomarker score from
                      the Shimadzu assay (AUC = 0.79, P = 0.67), it significantly
                      outperformed the Shimadzu Aβ42/40 ratio (AUC = 0.65, P =
                      0.037) and the Simoa Aβ42/40 assay (AUC = 0.57, P = 0.023).
                      Aβ biomarkers provided limited utility in distinguishing AD
                      from bvFTD. In contrast, pTau181 and GFAP exhibited strong
                      discriminatory power for differentiating AD from bvFTD, with
                      AUCs of 0.90 and 0.87, respectively. Combining pTau181 and
                      GFAP enhanced diagnostic accuracy, achieving an AUC of
                      0.94.We introduced a novel IP-MS assay that demonstrated
                      comparable precision to the Shimadzu composite score in
                      differentiating AD from non-neurodegenerative control
                      groups. However, Aβ levels did not enhance the
                      discrimination between AD and bvFTD. Furthermore, our
                      findings support the utility of combining pTau181 and GFAP
                      as a robust strategy for the blood-based differentiation of
                      AD and bvFTD.},
      keywords     = {Humans / Alzheimer Disease: blood / Alzheimer Disease:
                      diagnosis / Amyloid beta-Peptides: blood / Frontotemporal
                      Dementia: blood / Frontotemporal Dementia: diagnosis /
                      Diagnosis, Differential / Biomarkers: blood / Female / Aged
                      / Male / tau Proteins: blood / tau Proteins: cerebrospinal
                      fluid / Middle Aged / Peptide Fragments: blood / Glial
                      Fibrillary Acidic Protein: blood / Mass Spectrometry:
                      methods / Immunoprecipitation: methods / Neurofilament
                      Proteins: blood / Aged, 80 and over / Alzheimer’s disease
                      (Other) / Amyloid-beta (Other) / Blood biomarker (Other) /
                      Dementia (Other) / Differential diagnosis (Other) /
                      Frontotemporal lobar degeneration (Other) / Mass
                      spectrometry (Other) / Amyloid beta-Peptides (NLM Chemicals)
                      / Biomarkers (NLM Chemicals) / tau Proteins (NLM Chemicals)
                      / Peptide Fragments (NLM Chemicals) / Glial Fibrillary
                      Acidic Protein (NLM Chemicals) / amyloid beta-protein (1-42)
                      (NLM Chemicals) / GFAP protein, human (NLM Chemicals) /
                      neurofilament protein L (NLM Chemicals) / Neurofilament
                      Proteins (NLM Chemicals) / amyloid beta-protein (1-40) (NLM
                      Chemicals)},
      cin          = {AG Öckl},
      ddc          = {610},
      cid          = {I:(DE-2719)5000073},
      pnm          = {353 - Clinical and Health Care Research (POF4-353)},
      pid          = {G:(DE-HGF)POF4-353},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:39736793},
      pmc          = {pmc:PMC11687143},
      doi          = {10.1186/s13195-024-01647-w},
      url          = {https://pub.dzne.de/record/274026},
}